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Received December 22, 2011; accepted April 16, 2012AbstractBackground: The significance of lymph node involvement regarding the prognosis of primary duodenal adenocarcinoma remains controversial.
This study aims to evaluate the prognostic accuracy of nodal metastasis using the seventh edition American Joint Committee on Cancer staging
system in patients with primary duodenal adenocarcinoma.
Methods: Between 1993 and 2010, 36 patients who had undergone surgical resection for primary duodenal adenocarcinoma at the Kaohsiung
Veterans General Hospital were retrospectively reviewed.
Results: The median disease-free survival for all patients was 19 months and the median overall survival was 21 months. Lymph node metastases
were found in 26 (72%) of the patients, and 14 patients (39%) patients had in excess of three positive lymph nodes (N2). Patients with N2 disease
had significantly reduced overall survival, as compared to patients with three or fewer positive lymph nodes (N1; p ¼ 0.036). In univariate
analysis, factors including age >75 years, body weight loss, tumor size 4 cm, N2 disease and lymph node ratio >0.4 predicted shorter overall
survival. Multivariate analysis demonstrated that N2 and lymph node ratio >0.4 are significant risk factors associated with overall survival
( p ¼ 0.026 and p ¼ 0.042 respectively). N2 is also the only independent predictive factor for disease-free survival ( p ¼ 0.023).
Conclusion: Subdivision of metastatic lymph nodes into N1 and N2 improves predictive ability. The seventh edition American Joint Committee
on Cancer staging system is applicable in the present study with regard to the prediction of the prognosis for primary duodenal adenocarcinoma.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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1. Introduction distal bile duct cancers.2e4 Studies that focus only onPrimary duodenal adenocarcinoma is an uncommon tumor
that accounts for less than 0.5% of all gastrointestinal malig-
nancies.1 Because of the rarity of this type of cancer, it has
typically been reported together with jejunal and ileal tumors
as a small bowel cancer, or in some cases grouped with per-
iampullary malignancy, along with pancreatic, ampullary, and* Corresponding author. Dr. King-Tong Mok, Division of General Surgery,
Department of Surgery, Kaohsiung Veterans General Hospital, 386, Ta-Chung
First Road, Kaohsiung 813, Taiwan, ROC.
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1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2012.08.002duodenal adenocarcinoma are scarce.5,6 Correspondingly,
many questions regarding disease pathogenesis, natural
history, ideal medical management, and prognostic factors are
still unanswered.
Until now, the significance of lymph node involvement
regarding the prognosis of primary duodenal adenocarcinoma
remains controversial.7 However, some studies show a strong
negative impact on survival in lymph node metastatic
disease.6,8 The most common tool used to evaluate lymph
node metastasis is the American Joint Committee on Cancer
(AJCC) tumor-node-metatasis (TNM) staging system. Lymph
node staging is divided into two groups: no regional lymphhinese Medical Association. All rights reserved.
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according to the sixth edition of the AJCC TNM classification
system for small intestinal cancer published in 2002.9 In 2010,
the release of the seventh edition of AJCC classification
included major modifications to the lymph node staging
system.10 The previous N1 group is further subdivided into
new N1 (metastasis in 1e3 nodes) and N2 (metastasis in 4 or
more nodes). As a result, the Stage III disease is subclassified
into Stage IIIA (TxN1M0) and Stage IIIB (TxN2M0).
However, the clinical correlation of this change has yet to be
determined.
Apart from the involved lymph node, studies from other
cancers have suggested that the total number of lymph nodes
harvested is also an important indicator for prognosis because
an insufficient number evaluated may not provide an accurate
node staging.11e13 Consequently, the idea of lymph node ratio
(LNR) was introduced to eliminate the variation of dissection
techniques by different surgeons and the number of lymph
node harvested. This ratio is defined as the ratio of metastatic
nodes to the total number of lymph node examined. Evidence
presented in existing literature has demonstrated that the LNR
is inversely related to survival in esophageal, gastric, and
colon cancers.14e16
In this study, we aimed to clarify the prognostic impact of
lymph node status, including AJCC node staging, the total
number of lymph node examined, and the lymph node ratio in
patients with primary duodenal adenocarcinoma treated with
curative resection at a single medical center.2. Methods
The medical records of all patients with primary duodenal
adenocarcinoma who had undergone surgical resection at
Kaohsiung Veterans General Hospital between 1993 and 2010
were reviewed retrospectively. All patients enrolled in this
study had primary tumor located in the duodenum, and
histologically proven adenocarcinoma. Tumors arising from
ampulla of Vater, bile duct, and pancreas were excluded.
Patients whose pathologic reports were not available were also
excluded from the study.
A total of 36 patients met the inclusion criteria. Data for
each patient were collected, including age at diagnosis, clin-
ical presentation, type of surgery, postoperative course, and the
use of adjuvant therapy. Anemia was defined as hemoglobin
level <130 g/L in males, and <110 g/L in females. Pathologic
specimens were reviewed for tumor location, size, tumor
depth, histology, grade, surgical margin, pancreatic invasion,
number of metastatic lymph node, and number of lymph nodes
harvested. The lymph node ratio was calculated by dividing
the number of metastatic lymph nodes by the total number of
lymph nodes assessed. Patients were then subclassified into
four groups based on LNR (LNR ¼ 0; 0 < LNR  0.2;
0.2 < LNR  0.4; 0.4 < LNR). The cutoff value for each
group was determined by previous studies.3,17,18 The seventh
edition of AJCC classification for malignant neoplasms of the
small intestine was used for staging.Patients had regular postoperative follow-up examinations.
Tumor recurrence was identified using various diagnostic tools
such as sonography, computed tomography, magnetic reso-
nance imaging, positron emission tomography scan, and whole
body bone scan. Survival time and pattern of recurrence were
recorded. Distant metastasis was suspected if the distal lesion
was newly detected and did not appear in the preoperative
survey. Biopsy might be considered if the lesion was not in
any of the customary metastatic sites where duodenal adeno-
carcinoma is found (e.g. liver, peritoneum, lung). Informed
consent was obtained from all patients before operation. The
study complied with institutional review board protocols.
Statistical analyses were performed using SPSS 18.0 for
Windows (SPSS, Inc., Chicago, IL, USA). Disease-free
survival and overall survival were estimated by use of the
Kaplan-Meier method and differences were compared by log-
rank test. Multivariate comparisons were conducted using the
Cox proportional hazards model. Statistical significance was
considered at p < 0.05.
3. Results3.1. Patient characteristicsThe clinicopathological data of enrolled patients were
shown in Table 1. Of the 36 patients reviewed, 24 (67%) were
men and 12 (33%) were women. The median age at diagnosis
was 66 years (range 35e88). Most of the tumors were located
at the secondary portion of the duodenum (70%), followed by
eight (22%) at the first portion, two (5%) at the third portion,
and one case was found at the fourth portion. Also, 29 (80%)
patients underwent classic pancreaticoduodenectomy (Whip-
ple procedure) and two (6%) patients received pylorus-
preserving pancreaticoduodenectomy (PPPD). Segmental
duodenal resections were performed in five (14%) patients,
four of whom had a tumor at the first portion, and one patient
had a tumor at the fourth portion of the duodenum. All patient
surgical margins were disease-free, except for one patient in
the Whipple procedure group. Grossly, this patient’s resection
margins were free of tumor, but tumor cells were found
microscopically in the distal pancreatic cut end. The AJCC
nodal staging of this male patient was N2 and his LNR was
0.686 (11/16). He suffered from local recurrence 8 months
later.
The median tumor size was 4 cm in diameter and the depth
of tumor invasion was T4 in 72% of all patients. The median
number of lymph nodes harvested was 16 (range 5e38), and
10 (28%) patients had no metastatic lymph nodes with an LNR
of zero. Among the 26 patients who had positive lymph nodes,
12 patients had one to three positive lymph nodes (N1) and
were classified as Stage IIIA. The other 14 patients had more
than three positive lymph nodes (N2) and were classified as
Stage IIIB. When categorized by LNR, there were 11 (30%)
patients with LNR from 0 to 0.2, nine (25%) patients with
LNR from 0.2 to 0.4 and six (17%) with LNR > 0.4. All of the
eight (22%) patients who received adjuvant chemotherapy had
node-positive disease.
Table 1
Clinicopathologic features of 36 patients with primary duodenal
adenocarcinoma.
Feature n (%)
Age, y, median (range) 66 (35e88)
Male sex 24 (67)
Tumor location
First 8 (22)
Second 25 (70)
Third 2 (5)
Fourth 1 (3)
Type of surgery
Whipple 29 (80)
PPPD 2 (6)
Segmental resection 5 (14)
Surgical margin
Positive 1 (3)
Negative 35 (97)
Tumor size, cm, median (range) 4 (1.0e9.0)
Tumor depth (T-stage)
T1 1 (3)
T2 4 (11)
T3 5 (14)
T4 26 (72)
Nodal statusa
N0 10 (28)
N1 12 (33)
N2 14 (39)
TNM stageb
I 4 (11)
IIA 2 (6)
IIB 4 (11)
IIIA 12 (33)
IIIB 14 (39)
IV 0 (0)
Lymph node harvested, median (range) 16 (5e38)
Lymph node ratio (LNR)
0 10 (28)
0 < LNR  0.2 11 (30)
0.2 < LNR  0.4 9 (25)
<0.4 6 (17)
Grade
Well 3 (8)
Moderate 20 (56)
Poor 13 (36)
Adjuvant chemotherapy
Yes 8 (22)
No 28 (78)
Recurrence
No 17 (47)
Local 5 (14)
Distant 6 (17)
Local þ Distant 8 (22)
PPPD ¼ pylorus-preserving pancreaticoduodenectomy.
a N0, no positive lymph node; N1, 1e3 positive lymph nodes; N2, >3
positive lymph nodes.
b TNM stage: American Joint Committee on Cancer TNM staging system,
seventh edition.
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lymph node ratioFig. 1. Overall survival stratified by seventh edition American Joint Committee
on Cancer (AJCC) N stage. ( p < 0.001). N0 ¼ node negative; N1 ¼ 1e3
positive nodes; N2 ¼ >3 positive nodes.The median follow-up duration was 41 months for patients
who survived and 17 months for patients who died. The 5-year
overall survival rate of patients with N0, N1, and N2 disease(according to the current AJCC staging system) was 50%, 45%
and 0%, respectively, ( p < 0.001; Fig. 1). Patients with N2
disease had a significantly shorter overall survival rate
compared with patients with N0 and N1 disease ( p< 0.001 and
p¼ 0.036, respectively). However, no significant differencewas
detected in the overall survival between N0 and N1 disease
( p ¼ 0.238). Additionally, LNR is shown to be inversely
associated with overall survival when categorized into four
groups (LNR ¼ 0; 0 < LNR  0.2; 0.2 < LNR  0.4;
0.4< LNR). Their 3- and 5-year overall survival rate were 90%,
31%, 29%, 0%, 50%, 31%, 0%, and 0%, ( p¼ 0.011). However,
there is no one distinctive LNR group that has a significant
difference in overall survival in comparison with the other three
groups (Fig. 2).
Nineteen out of the 36 patients (53%) had recurrence of
their cancer. The median time to recurrence after operation
was 9 months (range 3e46). Local recurrence occurred in
five (14%) cases and distant metastasis in six (17%) cases.
Concurrent local and distant metastases were documented in
the remaining eight (22%) cases. The liver was the most
common site of distant metastasis followed by the perito-
neum, lung, and bone. Palliative chemotherapy was given to
three of the 19 recurrent patients (16%). Disease-free survival
rates at 3 and 5 years for all 36 patients were 39% and 35%,
respectively. Both the AJCC node classification and LNR
were significantly associated with disease-free survival
( p ¼ 0.021 and 0.040, respectively; Fig. 3 and Fig. 4). In
subgroup analysis, N2 disease had shorter median disease-
free survival compared with N1 disease, but it did not
reach statistical significance (8 months vs. 13 months,
p ¼ 0.174).
Fig. 2. Overall survival stratified by lymph node ratio ( p ¼ 0.011).
LNR ¼ lymph node ratio.
Fig. 4. Disease-free survival stratified by lymph node ratio ( p ¼ 0.040).
LNR ¼ lymph node ratio.
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age >75 years ( p ¼ 0.020), body weight loss ( p ¼ 0.037),
tumor size 4 cm ( p ¼ 0.041), AJCC N2 disease ( p < 0.001)
(Fig. 5) and LNR > 0.4 ( p ¼ 0.014) were associated with
decreased overall survival (Table 2). Gender, anemia, tumorFig. 3. Disease-free survival stratified by seventh edition American Joint
Committee on Cancer (AJCC) N stage ( p ¼ 0.021). N0 ¼ node negative;
N1 ¼ 1e3 positive nodes; N2 ¼ >3 positive nodes.grade, T stage, tumor location, total lymph node examined,
LNR > 2, pancreatic invasion, and the use of adjuvant
chemotherapy had no significant influence on overall survival.
Subsequent multivariate analysis using 2 different models
were performed to avoid a confounding effect by putting the
two lymph node factors (N2 disease, LNR > 0.4) together.
The results demonstrated that N2 disease (hazard ratio ¼ 3.48,Fig. 5. Overall survival stratified by positive lymph node > 3 and 3
( p < 0.001).
Table 2
Univariate analysis for factors associated with overall survival.
Factors N Median
survival
(mo)
Survival
(%)
p
3-y 5-y
Age (y)
75 29 23 50 30 0.020
>75 7 5 17 17
Gender
Male 24 18 45 25 0.886
Female 12 21 42 31
Anemiaa
Yes 22 23 49 38 0.291
No 14 18 35 9
Body weight loss
Yes 12 10 18 9 0.037
No 24 46 57 35
Grade
Well þ Moderate 24 21 45 35 0.199
Poor 12 18 44 0
T stage
T1 þ T2 þ T3 10 56 70 35 0.296
T4 26 18 33 22
Tumor size (cm)
4 21 18 30 10 0.040
>4 15 61 66 55
Tumor location
Second portion 25 18 43 22 0.743
Other portion (first, third,fourth) 11 23 47 35
Lymph node metastasis, n
0e3 (N0, N1) 22 56 67 43 <0.001
>3 (N2) 14 13 8 0
Total lymph nodes examined
<12 9 18 50 50 0.296
12 27 21 43 21
Lymph node ratio
0.2 21 55 57 34 0.286
>0.2 15 17 24 12
Lymph node ratio
0.4 30 41 51 31 0.014
>0.4 6 13 0 0
Pancreatic invasion
Yes 18 16 28 17 0.224
No 18 55 64 37
Adjuvant chemotherapy
Yes 8 16 25 13 0.218
No 28 46 50 32
a Anemia was defined as hemoglobin level <130 g/L in male and <110 g/L
in female respectively.
Table 3
Multivariate analysis for factors associated with overall survival.
Factors Hazard ratio 95% CI p
Model 1
Age >75 y 2.79 0.89e8.77 0.079
Body weight loss 2.06 0.87e4.85 0.100
Tumor size 4 cm 1.48 0.56e3.90 0.432
>3 LN metastases (N2) 3.48 1.18e10.22 0.024
Model 2
Age >75 y 4.78 1.58e14.50 0.006
Body weight loss 2.60 1.12e6.06 0.026
Tumor size 4 cm 2.20 0.91e5.28 0.078
LNR > 0.4 4.25 1.38e13.10 0.012
LN ¼ lymph node; LNR ¼ lymph node ratio; CI ¼ confidence interval.
Fig. 6. Disease-free survival stratified by positive lymph node >3 and 3
( p ¼ 0.010).
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were significant prognostic predictors (Table 3).
With respect to recurrence, anemia ( p ¼ 0.004), poor tumor
grade ( p ¼ 0.017), tumor size 4 cm ( p ¼ 0.008), AJCC N2
disease ( p ¼ 0.010; Fig. 6), LNR > 0.4 ( p ¼ 0.026) and
pancreatic invasion ( p ¼ 0.028) were found to have a signifi-
cant negative impact on disease-free survival by univariate
analysis (Table 4). Similarly, 2 separate models were con-
structed using the Cox proportional hazards model to assess
the influence of lymph node evaluation in disease-free
survival. When multivariate analysis was employed,
LNR > 0.4, along with anemia, tumor grade, and pancreatic
invasion lost their prognostic significance. Only N2 diseaseremained as an independent factor predicting tumor recurrence
(hazard ratio ¼ 3.36, p ¼ 0.023; Table 5).4. Discussion
The principal goal of this study was to determine whether
LN status, especially the new AJCC N-stage was associated
with survival. Lymph node metastasis is a well-known prog-
nostic factor for many gastrointestinal and periampullary
malignancies.19e22 When LN assessment occurs in the context
of duodenal adenocarcinoma, however, there is some
disagreement in this area.7 Our data, in accordance with many
other reports, have shown that patients with nodal metastases
have diminished survival ( p < 0.001).6e8,23e25 However,
other studies have found no such relationship.1,26,27 The
incidence of lymph node metastasis in patients with duodenal
adenocarcinoma has been reported to range from 22% to
Table 4
Univariate analysis for factors associated with disease-free survival.
Factors N Median
survival (mo)
Survival
(%)
p
3-y 5-y
Age (y)
75 29 14 41 37 0.801
>75 7 19 33 33
Gender
Male 24 27 43 37 0.644
Female 12 13 33 33
Anemia
Yes 22 NR 58 58 0.004
No 14 10 15 8
Body weight loss
Yes 12 12 33 33 0.638
No 24 27 42 36
Grade
Well þ Moderate 24 34 50 50 0.017
Poor 12 9 20 0
T stage
T1 þ T2 þ T3 10 46 63 47 0.248
T4 26 13 31 31
Tumor size (cm)
4 21 11 19 13 0.008
>4 15 NR 68 68
Tumor location
Second portion 25 19 37 31 0.661
Other portion (first, third,fourth) 11 13 44 44
Lymph node metastases, n
0e3 (N0, N1) 22 NR 56 51 0.010
>3 (N2) 14 8 0 0
Total lymph nodes examined
<12 9 14 50 50 0.564
12 27 19 36 31
Lymph node ratio
0.2 21 27 47 42 0.528
>0.2 15 14 17 17
Lymph node ratio
0.4 30 34 46 41 0.026
>0.4 6 5 0 0
Pancreatic invasion
Yes 18 11 28 21 0.028
No 18 NR 54 54
Adjuvant chemotherapy
Yes 8 12 13 13 0.159
No 28 46 51 45
NR ¼ not reached median survival rates of 50.0%.
Table 5
Multivariate analysis for factors associated with disease-free survival.
Factors Hazard ratio 95% CI p
Model 1
Anemia 2.31 0.61e8.69 0.216
Grade, poor 1.56 0.48e5.07 0.459
Tumor size 4 cm 1.07 0.25e4.49 0.928
>3 LN metastasis (N2) 3.36 1.18e9.55 0.023
Pancreatic invasion 1.87 0.60e5.75 0.278
Model 2
Anemia 1.70 0.42e6.88 0.461
Grade, poor 1.44 0.44e4.75 0.549
Tumor size 4 cm 1.88 0.43e8.27 0.406
LNR > 0.4 2.23 0.66e7.53 0.199
Pancreatic invasion 1.47 0.47e4.65 0.508
LN ¼ lymph node; LNR ¼ lymph node ratio.
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ment. Given the relatively high percentage of nodal metastasis
in our study, it is reasonable that our 5-year survival rate of
26% appeared to be lower in compared with other series
(25e75%).7
In this study, we found that the overall survival rate of
patients with one to three positive lymph nodes (N1) did not
differ significantly from that of patients without lymph node
metastasis (N0; p ¼ 0.238). On the contrary, more than three
lymph nodes involved (N2) was an independent predictor of
overall and disease-free survival ( p ¼ 0.024 and p ¼ 0.023,
respectively). Similar results had been found in patients with
pancreatic carcinoma.22,29e31 Zacharias et al31 reported no
statistically significant difference in survival between patientswith a single metastatic node and patients with negative lymph
nodes. However, they did find that patients with no more than
one metastatic lymph node survived significantly longer than
patients with two or more involved lymph nodes. They
concluded that the presence of two or more positive lymph
nodes was a major prognostic factor after resection of
pancreatic carcinoma. These results also implied that a small
number of positive lymph nodes might not affect clinical
outcome, and that a subdivision according to the number of
metastatic lymph nodes should be considered to provide better
prognostic value.
Regarding small bowel adenocarcinoma, Overman et al.32
demonstrated evident improvement in prognostic efficacy by
stratifying patients with nodal metastasis into those patients
with fewer than three positive lymph nodes and those with
three or more positive lymph nodes (hazard ratio 1.44; 95%
confidence interval 1.12e1.86). The 5-year disease-specific
survival rates of the two subgroups were 58% and 37%
respectively. The selected cutoff point for the number of
positive lymph node in their study was slightly different
compared with the seventh edition of AJCC N-staging (3 vs.
>3 positive lymph nodes). Because in Overman’s study,
patients with tumors located in jejunum, ileum, and non-
specified locations were all included. When all circumstances
were factored in, it could not be determined whether more
than three positive lymph nodes is the cutoff value that has the
best prognostic success in patients with duodenal adenocar-
cinoma. Based on our study, we clearly demonstrated that
having more than three lymph node metastases (N2) is the
most important factor to predict survival after curative resec-
tion. To our knowledge, this study is the first to validate the
significant association between survival and N-staging of the
seventh edition AJCC classification in patients with duodenal
adenocarcinoma.
There were five (14%) patients in our series who received
segmental resection of the duodenum. Some investigators have
proposed a pancreaticoduodenectomy procedure for all
duodenal adenocarcinoma regardless of tumor location.1
Others suggest duodenal segmentectomy as a less morbid
choice for tumors located in the first, third, or fourth portions
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lymph node clearance are the two major concerns for limited
resection.34 Kaklamanos et al23 justified the use of segmental
resection by showing a comparable number of lymph nodes
removed, whether a pancreaticoduodenectomy or a duodenal
segmentectomy was performed. A similar result was also
found in our study ( p ¼ 0.436). Furthermore, no patient in our
limited resection group had surgical margins involved by
tumor. In all, our data support the use of the segmental
resection procedure in selected patients with duodenal
adenocarcinoma.
The total number of lymph nodes examined did not affect
survival in our study (overall survival, p ¼ 0.296; disease-free
survival, p ¼ 0.564) and in a small series reported by Struck
et al.35 Nevertheless, several investigators proposed that an
inadequate number of lymph nodes removed may impair
prognostic discrimination due to inaccurate assessment of
lymph node metastasis, which might understage cancer
patients.3,24,32 The correlation between survival and the
number of total lymph node evaluated have also been shown in
esophageal, gastric, pancreatic, and colorectal cancers.11e13,36
However, the exact number of lymph nodes that needed to be
removed varied from study to study. For example, in pancre-
atic adenocarcinoma, the proposed number of lymph nodes
that should be collected was reported to be 10, 12, or 15
nodes.13,17,37
In a retrospective review of 522 patients with resected
periampullary malignancies, Hurtuk et al3 found that LNR is
inversely associated with survival in pancreatic and ampullary
cancer, but not in bile duct and duodenal cancer. In contrast,
our results showed that LNR is predictive of disease-free
survival and overall survival in patients with primary
duodenal adenocarcinoma by categorizing patients into four
groups using the same LNR cutoff values of 0, 0.2, and 0.4
( p ¼ 0.011 and p ¼ 0.040 respectively). Besides, LNR > 0.4
was identified as an independent prognostic factor for overall
survival ( p ¼ 0.012). Two studies of small bowel adenocar-
cinoma also reported significantly reduced survival rates in
patients with LNR  0.5 and LNR  0.75, respectively.4,38
Theoretically, LNR is more discriminative than the number
of positive lymph nodes (N-stage) in prognostic prediction
because it incorporates the extent of lymphadenectomy.
Furthermore, LNR may also eliminate the variation on spec-
imen examination by different pathologists (e.g., the number
of lymph nodes harvested).17 Certain reports of cases of
gastric and breast cancer have already demonstrated the
prognostic efficacy of LNR and its superiority over current
AJCC nodal staging categories.15,39 In the current study, more
than three positive lymph nodes (N2 disease) exhibited prog-
nostic value in both disease-free and overall survival rates,
while LNR >0.4 failed to influence disease-free survival using
multivariate analysis. Based on our findings, the number of
metastatic lymph nodes was the more potent prognostic factor
after resection of primary duodenal adenocarcinoma.
Another interesting finding of the present study was that
smaller tumors (4 cm) were associated with a significantly
poorer outcome than were larger ones (>4 cm) in univariateanalysis (overall survival, p ¼ 0.040; disease-free survival,
p ¼ 0.008). This seemingly counterintuitive result has also
been observed by Hurtuk et al,40 who found that larger tumors
were less likely to behave aggressively. On the contrary,
smaller tumors had a predilection to invade periduodenal fat or
nearby structures. Furthermore, when they focused on tumors
that invaded nearby structures, patients with larger tumors still
showed better prognosis than those with smaller tumors. The
authors explained those results by hypothesizing that there
were differences in biological behaviors between duodenal
adenocarcionomas and some tumors that tend to be less
aggressive. Further study is required to clarify the biologic
nature of this tumor. However, in the meantime, the authors
suggested patients undergo aggressive surgical resection
regardless of the tumor size.40
In conclusion, our data validate the predictive power of
nodal metastasis using N classification of the seventh edition
AJCC staging system. More than three positive lymph nodes
(N2 disease) is the most important prognostic factor in patients
with primary duodenal adenocarcinoma after curative resec-
tion. The prognostic efficacy of LNR is promising and worthy
of further larger scale research.
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